Paradoxical clinical effect of estrogen on breast cancer risk: A "new" biology of estrogen-induced apoptosis

Cancer Prevention Research

Volumn 4, Issue 5, 2011, Pages 633-637

  Jordan, V Craig ^a   Ford, Leslie G ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DIETHYLSTILBESTROL; ESTRADIOL; FAS LIGAND; LETROZOLE; RALOXIFENE; TAMOXIFEN;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; DRUG EFFICACY; DRUG MEGADOSE; ESTROGEN THERAPY; HORMONE RESISTANCE; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

APOPTOSIS; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; RISK FACTORS;

EID: 79955870520     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0185     Document Type: Review

References (28)

1. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
2. Levenson AS, Jordan VC. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 1997;57:3071-8. (Pubitemid 27351713)
3. Jordan VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 2009;69:1243-54.
4. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62. (Pubitemid 41672231)
5. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
6. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res 2010;3:696-706.
7. La Croix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14.
8. Jordan VC. The 38th David A. Karnofsky Lecture: the paradoxical actions of estrogen in breast cancer - survival or death? J Clin Oncol 2008;26:3073-82.
9. Haddow A, Watkinson JM, Paterson E, Koller PC. Influence of synthetic oestrogens on advanced malignant disease. Br Med J 1944;2:393-8.
10. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 1990;50:4177-89. (Pubitemid 20225648)
11. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981;304:16-21. (Pubitemid 11212892)
12. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999;54:117-22. (Pubitemid 29295314)
13. Haddow A, David A. Karnofsky memorial lecture. Thoughts on chemical therapy. Cancer 1970;26:737-54.
14. Brunner N, Spang-Thomsen M, Vindelov L, Nielsen A. Effect of 17 beta-oestradiol on growth curves and flow cytometric DNA distribution of two human breast carcinomas grown in nude mice. Br J Cancer 1983;47:641-7. (Pubitemid 13094901)
15. Brunner N, Bastert GB, Poulsen HS, Spang-Thomsen M, Engelholm SA, Vindelov L, et al. Characterization of the T61 human breast carcinoma established in nude mice. Eur J Cancer Clin Oncol 1985;21:833-43. (Pubitemid 15028510)
16. Wolf DM, Jordan VC. A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 1993;127:23-33.
17. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000;6:2028-36. (Pubitemid 30305102)
18. Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2003;95:1586-97. (Pubitemid 37455926)
19. Balaburski GM, Dardes RC, Johnson M, Haddad B, Zhu F, Ross EA, et al. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol 2010;37:387-98.
20. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001;93:1714-23. (Pubitemid 33130260)
21. Jordan VC, Liu H, Dardes R. Re: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol and the two faces of Janus: sex steroids as mediators of both cell proliferation and cell death. J Natl Cancer Inst 2002;94:1173-5.
22. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67:111-6. (Pubitemid 32744491)
23. Lonning PE. Additive endocrine therapy for advanced breast cancer - back to the future. Acta Oncol 2009;48:1092-101.
24. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009;302:774-80.
25. Maximov PY, Lewis-Wambi JS, Jordan VC. The paradox of oestradiol-induced breast cancer cell growth and apoptosis. Curr Signal Transduct Ther 2009;4:88-102.
26. Lewis-Wambi JS, Jordan VC. Estrogen regulation of apoptosis: howcan one hormone stimulate and inhibit? Breast Cancer Res 2009;11:206.
27. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 2003;95:1597-608. (Pubitemid 37455927)
28. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005;97:1746-59. (Pubitemid 41782284)